Publications
5808 Results
- Journal / Conference
- Journal of Clinical Oncology Dec 20;37(36):3484-3492; Oct 28[Online ahead of print]
- Year
- 2019
- Research Committee(s)
- Breast
- PMID
- PMID31657982
- PMC
- PMC7194448
- Study Number(s)
- SWOG-9313
Validation of the DNA Damage Immune Response (DDIR) Signature in Triple-Negative Breast Cancer (TNBC) Patients from the SWOG 9313c Trial
- Journal / Conference
- ASTRO Annual Meeting (9/15-18/2019, Chicago IL), oral
- Year
- 2019
- Research Committee(s)
- Breast
- Study Number(s)
- N9831
Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 10-14, 2019, San Antonio, TX), P2-18-03, poster
- Year
- 2019
- Research Committee(s)
- Breast
- Study Number(s)
- S0307
Fractures in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG S0307 trial (ClinicalTrials.gov Identifier: NCT00127205)
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 10-14, 2019, San Antonio, TX), poster, spotlight session
- Year
- 2019
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1105
Baseline Factors Associated with Aromatase Inhibitor Adherence Failure among Women in Enrolled in a Randomized Trial of Text-Messaging: SWOG S1105
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 291, abst 613 (American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
- Year
- 2019
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106, S1203, SWOG-8600, SWOG-9031, SWOG-9333
Increasing lengths of first complete remission with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 1366. American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), TIPS, poster
- Year
- 2019
- Research Committee(s)
- Leukemia
Alliance A041701 - A randomized phase 2/3 study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute myeloid leukemia receiving intensive induction chemotherapy
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 751, abst 623; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
- Year
- 2019
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/E1411
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 4092, abst 626; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
- Year
- 2019
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/E1412
Factors That Potentially Impact Lenalidomide/R-CHOP (R2-CHOP) Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 349; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
- Year
- 2019
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1001
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup NCTN Study S1001
- Journal / Conference
- Blood (2019) 134 (Supplement_1): 2771; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
- Year
- 2019
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0016